Orexo AB said on Wednesday that Zubsolv tablet’s position has changed from excluded from reimbursement to reimbursed as a preferred product. Zubsolv is buprenorphine and naloxone sublingual tablet (CIII) managed care formulary position with CVS Caremark for patients suffering from opioid dependence.
CVS Caremark, one of the largest PBMs in the United States, published their 2018 Exclusion Template Formulary List of Covered Drugs for their commercial clients. Effective January 1, 2018, Zubsolv will be placed in a preferred parity position with the market-leading branded product and the generic will remain in the generic tier, Orexo said. This change in formulary for 2018 means that Zubsolv increased its unrestricted access to over 90 percent of all commercial managed care lives in the United States.
Nikolaj Sørensen, CEO and President Orexo AB, said: “I am very pleased with this positive news and the decision by CVS Caremark to again include Zubsolv as a co-preferred product. We have maintained a strong confidence that we would regain the lost preferred position and through significant efforts from our US commercial organization we have succeeded. To be able to compete in the US market, market access is the cornerstone of our commercial strategy in helping patients in the growing opioid epidemic. The inclusion of Zubsolv on the CVS Caremark formulary is a significant step forward to secure Zubsolv gains universal coverage for all patients with commercial insurance and continued profitable growth for Orexo.”